Dell Technologies Inc. (NYSE: DELL): What EMC’s $984.3 m Air Force award means for defense IT strategy
Read More Pharma Industry News Millendo Therapeutics begins human trial of VMS drug candidate MLE-301 Millendo Therapeutics has started a phase 1 clinical trial of its selective neurokinin 3 receptor (NK3R) antagonist MLE-301,… bypharmanewsdailySeptember 24, 2020